Abstract
Newer direct-acting antiviral agents have revolutionized the medical management of chronic hepatitis C. In addition to being extremely efficacious, they report very mild adverse drug reactions from experience in clinical trials. However, because they are relatively new on the horizon, postmarketing surveillance studies refining the safety profile are not yet available. We present a case of seizures as a potential side effect of antiviral therapy with sofosbuvir and simeprevir.
Original language | English (US) |
---|---|
Pages (from-to) | e570-e571 |
Journal | American journal of therapeutics |
Volume | 23 |
Issue number | 2 |
DOIs | |
State | Published - Mar 1 2016 |
Keywords
- adverse drug reaction
- direct-acting antivirals
- hepatitis C
- pharmacokinetics
- side effect
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology